Novo Nordisk stock falls after raised forecast fails to change the debate over its obesity business

Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.

# Novo Nordisk stock falls after raised forecast fails to change the debate over its obesity business Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies. **Read the full article:** [CNBC](https://www.cnbc.com/2026/08/05/novo-nordisk-stock-guidance-earnings-wegovy-ozempic-eli-lilly.html) *This article was originally published by CNBC. MoneyWiseInc provides expert curation of the best financial content from trusted sources.*